27 January 2021 | News
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
Image Credit: shutterstock.com
BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have announced that according to the Food and Health Bureau of the Hong Kong Special Administrative Region of the PRC, the COVID-19 vaccine COMIRNATY® (also known as BNT162b2) based on BioNTech's proprietary mRNA technology has received emergency use authorisation (EUA) in Hong Kong.
The vaccine will be produced in BioNTech's manufacturing facilities in Germany, and supplied to Hong Kong for administration under the Hong Kong SAR Government's COVID-19 Vaccination Program.
"We are excited and encouraged that COMIRNATY® has been authorized to emergency use in Hong Kong. This is an important milestone in the joint efforts of BioNTech and Fosun Pharma to achieve vaccine accessibility globally. We will continue working closely with BioNTech to complete the ongoing clinical trial and marketing registration in Greater China," Wu Yifang, Chairman and CEO of Fosun Pharma said. "We will also cooperate closely with HKSAR regarding vaccination deployment plan to ensure that Hong Kong citizens can receive a well-tolerated and effective mRNA COVID-19 vaccine as soon as possible in order to protect the health of millions of households."
COMIRNATY® is a COVID-19 vaccine which is based on messenger RNA, a natural molecule that acts like a blueprint providing instructions for human cells to make a target protein, or antigen, which activates the body's immune response against the respective virus.